Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety…
NCT00423202 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00423202 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. |
| Official title | Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Arterial Hypertension |
| Intervention type | Drug |
| Interventions | ambrisentan |
| Enrollment | 186 |
| Start date | Dec 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Jan 18, 2007 |
| Last update posted | Apr 16, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: